Literature DB >> 23532497

Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis.

Min Ni1, Wei Wei, Yichao Wang, Na Zhang, Hongmei Ding, Chen Shen, Fang Zheng.   

Abstract

OBJECTIVE: The aim of our study was to investigate the contribution of serum calreticulin (CRT) in the assessment of disease activity in rheumatoid arthritis (RA).
METHODS: Serum CRT levels were measured by ELISA in 70 patients with established RA, 30 systemic lupus erythematosus (SLE), 25 other autoimmune diseases, 20 osteoarthritis (OA), and 35 of healthy controls (HC). Correlations of CRT serum levels with disease activity [Disease Activity Score for 28 joints (DAS28)], erythrocyte sedimentation rate(ESR) and C-reactive protein (CRP) were assessed. Serum CRT levels were also detected in RA patients whose RF, anti-CCP and anti- MCV antibodies were positive and negative.
RESULTS: Serum CRT levels in RA patients (4.817 ± 2.425 ng/ml) was significantly higher (P <0.05) compared with those in the serum of OA (3.574 ± 0.942 ng/ml), SLE (4.013 ± 1.536 ng/ml), other autoimmune diseases (3.882 ± 0.837 ng/ml) and HC (3.726 ± 0.627 ng/ml). Significant positive correlation of CRT with DAS28, ESR and CRP was found in RA patients. Furthermore, RA patients whose anti-CCP and anti-MCV antibodies were positive had higher levels of CRT (P < 0.01).
CONCLUSION: Serum CRT levels were increased in patients with RA compared with those controls. Moreover, a significant correlation was observed between serum CRT levels and disease activity in RA. It might be used as a potential biomarker for clinical diagnosis and provide additional information regarding disease activity along with the traditional indices such as ESR and CRP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532497     DOI: 10.1007/s10875-013-9885-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

1.  Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells.

Authors:  Joanna M Tarr; Paul G Winyard; Brent Ryan; Lorna W Harries; Richard Haigh; Nick Viner; Paul Eggleton
Journal:  Arthritis Rheum       Date:  2010-10

2.  The Disease Activity Score and the EULAR response criteria.

Authors:  J Fransen; P L C M van Riel
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.

Authors:  Sumeet Agrawal; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

Review 5.  Pathophysiological roles of calreticulin in autoimmune disease.

Authors:  P Eggleton; D H Llewellyn
Journal:  Scand J Immunol       Date:  1999-05       Impact factor: 3.487

Review 6.  A role for calreticulin in the pathogenesis of rheumatoid arthritis.

Authors:  Joseph Holoshitz; Denise E De Almeida; Song Ling
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

7.  Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.

Authors:  Rogier M Thurlings; Koen Vos; Daniëlle M Gerlag; Paul P Tak
Journal:  Arthritis Rheum       Date:  2008-12

8.  Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.

Authors:  Toshihiro Matsui; Yoshiaki Kuga; Atsushi Kaneko; Jinju Nishino; Yoshito Eto; Noriyuki Chiba; Masayuki Yasuda; Koichiro Saisho; Kota Shimada; Shigeto Tohma
Journal:  Ann Rheum Dis       Date:  2007-03-16       Impact factor: 19.103

9.  Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity.

Authors:  Laurindo Ferreira da Rocha; Ângela Luzia Branco Pinto Duarte; Andréa Tavares Dantas; Henrique Ataíde Mariz; Ivan da Rocha Pitta; Suely Lins Galdino; Maira Galdino da Rocha Pitta
Journal:  J Rheumatol       Date:  2012-05-15       Impact factor: 4.666

10.  Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes.

Authors:  Vincent Goëb; Marlène Thomas-L'Otellier; Romain Daveau; Roland Charlionet; Patrice Fardellone; Xavier Le Loët; François Tron; Danièle Gilbert; Olivier Vittecoq
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more
  16 in total

1.  Calreticulin promotes angiogenesis via activating nitric oxide signalling pathway in rheumatoid arthritis.

Authors:  H Ding; C Hong; Y Wang; J Liu; N Zhang; C Shen; W Wei; F Zheng
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

2.  Peripheral blood mononuclear cell proteome profile in Behçet's syndrome.

Authors:  Asli Kirectepe Aydin; Yeşim Özgüler; Didar Uçar; Murat Kasap; Gürler Akpınar; Emire Seyahi; Eda Tahir Turanli
Journal:  Rheumatol Int       Date:  2019-08-14       Impact factor: 2.631

Review 3.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

4.  TNF-α/calreticulin dual signaling induced NLRP3 inflammasome activation associated with HuR nucleocytoplasmic shuttling in rheumatoid arthritis.

Authors:  Yixin Liu; Wei Wei; Yang Wang; Chunyou Wan; Yingyu Bai; Xuguo Sun; Jun Ma; Fang Zheng
Journal:  Inflamm Res       Date:  2019-05-22       Impact factor: 4.575

5.  Serum calreticulin as a novel biomarker of juvenile idiopathic arthritis disease activity.

Authors:  Nashwa Ismail Hashaad; Rasha Mohamed Fawzy; Abeer Ahmed Abo Elazem; Mohamed Ibrahim Youssef
Journal:  Eur J Rheumatol       Date:  2017-03-01

6.  CD1d(hi)CD5⁺ B cells differentiate into antibody-secreting cells under the stimulation with calreticulin fragment.

Authors:  Tengteng Zhang; Yun Xia; Lijuan Zhang; Wanrong Bao; Chao Hong; Xiao-Ming Gao
Journal:  Protein Cell       Date:  2013-11-10       Impact factor: 14.870

7.  Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.

Authors:  Yichao Wang; Jiaogui Xie; Zhili Liu; Hongwei Fu; Qianyu Huo; Yajun Gu; Yunde Liu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

8.  Label-free proteomics identifies Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy.

Authors:  Chantal A Mutsaers; Douglas J Lamont; Gillian Hunter; Thomas M Wishart; Thomas H Gillingwater
Journal:  Genome Med       Date:  2013-10-18       Impact factor: 11.117

Review 9.  Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis.

Authors:  Xiaoyin Niu; Guangjie Chen
Journal:  J Immunol Res       Date:  2014-08-21       Impact factor: 4.818

10.  Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.

Authors:  Hiroyuki Inoue; Hirono Tsutsumi; Kentaro Tanaka; Eiji Iwama; Yoshimasa Shiraishi; Aiko Hirayama; Takayuki Nakanishi; Hiroyuki Ando; Maako Nakajima; Seiji Shinozaki; Hiroaki Ogata; Kazuyasu Uryu; Koji Okamura; Shinichi Kimura; Tomohiro Ogawa; Keiichi Ota; Yasuto Yoneshima; Naoki Hamada; Yoichi Nakanishi; Isamu Okamoto
Journal:  Transl Lung Cancer Res       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.